Canakinumab (Ilaris) — CPB 0881 | AETNA Coverage Update

TL;DR: Aetna, a CVS Health company, modified CPB 0881 covering canakinumab (Ilaris) effective September 26, 2025. Here's what billing teams need to know before submitting claims under HCPCS J0638.

Aetna updated its canakinumab coverage policy under CPB 0881 Aetna system, with the revised policy carrying an effective date of September 26, 2025. The primary billing code at stake is HCPCS J0638 (injection, canakinumab, 1 mg), administered via CPT 96372 (subcutaneous or intramuscular injection). This policy also explicitly lists TNF inhibitors and other biologics as non-covered alternatives for the indications addressed in this bulletin — a list that runs 13 HCPCS codes deep and creates real claim denial risk if your team isn't clear on the distinction.

Quick-Reference Table

Aetna Canakinumab Coverage Criteria and Medical Necessity Requirements 2025

Canakinumab (Ilaris) billing under Aetna requires precertification — full stop. This is not plan-design-dependent for most Aetna commercial members. All Aetna participating providers must get prior authorization before administering the drug. Call (866) 752-7021 or fax (888) 267-3277 to initiate precertification.

The coverage policy governs commercial medical plans only. If you're billing Medicare Advantage or Medicare Part B, Aetna directs you to separate Part B criteria at their Medicare step-therapy page. Don't apply commercial CPB 0881 criteria to Medicare claims — those are governed by a different standard.

Medical necessity under this coverage policy is tied to specific diagnoses. The ICD-10-CM code list under CPB 0881 spans 321 codes, covering conditions across multiple therapeutic areas. The primary categories represented include:

Medical necessity documentation must support the specific ICD-10 code you bill. A diagnosis that doesn't map to the covered code list won't survive a coverage review, regardless of clinical rationale.

Aetna's prior authorization requirement for J0638 is firm. If your team administers canakinumab without precertification in hand, you're looking at a claim denial with limited recourse. Build the prior auth step into your workflow before scheduling infusion or injection appointments.

Aetna Canakinumab Exclusions and Non-Covered Indications

This is where CPB 0881 gets operationally significant for billing teams. Aetna explicitly lists 13 HCPCS codes as not covered for indications listed in this CPB. These are all TNF inhibitors and related biologics — drugs that might otherwise be used for overlapping inflammatory conditions.

The non-covered codes under CPB 0881 are:

The practical issue here is step therapy. Aetna's canakinumab policy likely requires trials of conventional therapies before approving J0638. The non-covered list signals that Aetna does not view TNF inhibitors as covered alternatives for the specific indications this CPB addresses. If a patient has already failed TNF therapy and you're billing J0638 as the next step, that's the scenario where prior auth documentation becomes critical.

Don't submit J0139, J1438, or any of the adalimumab biosimilar Q-codes as a substitute or concurrent therapy billing for the indications in this CPB. Aetna has drawn a hard line. A claim denial on those codes for these indications is the expected outcome — not an administrative error.

Coverage Indications at a Glance

Aetna Canakinumab Billing Guidelines and Action Items 2025

CPT, HCPCS, and ICD-10 Codes for Canakinumab Under CPB 0881

Covered HCPCS Code (When Selection Criteria Are Met)

Not Covered HCPCS Codes (For Indications Listed in CPB 0881)

Key ICD-10-CM Diagnosis Codes

The full code set under CPB 0881 includes 321 ICD-10-CM codes. The table below covers the primary categories represented in the policy data provided.

For the complete ICD-10-CM code list under CPB 0881, access the full policy at app.payerpolicy.org/p/aetna/0881.